Telo Genomics Corp. TDSGF
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 41.40% | -2.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.15% | -3.80% | |||
| Operating Income | -11.15% | 3.80% | |||
| Income Before Tax | -11.15% | 3.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.18% | 3.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.18% | 3.97% | |||
| EBIT | -11.15% | 3.80% | |||
| EBITDA | -9.60% | 6.94% | |||
| EPS Basic | -7.89% | 2.56% | |||
| Normalized Basic EPS | -8.33% | 0.00% | |||
| EPS Diluted | -1.39% | 1.37% | |||
| Normalized Diluted EPS | -8.33% | 0.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||